Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/20/2/294/392501/mdn601.pdf
Reference16 articles.
1. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial;Lancet,2002
2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study;Ozols;J Clin Oncol,2003
3. Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome;Riedinger;Ann Oncol,2007
4. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study;Riedinger;Ann Oncol,2006
5. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer;van der Burg;Ann Oncol,1990
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer;Gynecologic Oncology;2022-11
2. Role of 18F FDG PET/CT in evaluation of post-operative ovarian carcinoma;Egyptian Journal of Radiology and Nuclear Medicine;2022-09-01
3. PET/TC con18F-FDG en la recurrencia del cáncer de ovario: Impacto clínico, correlación con TC con contraste iv y CA-125, y valor pronóstico;Revista Española de Medicina Nuclear e Imagen Molecular;2021-07
4. 18F-FDG PET/CT in ovarian cancer recurrence: Clinical impact, correlation with ceCT and CA-125, and prognostic value;Revista Española de Medicina Nuclear e Imagen Molecular (English Edition);2021-07
5. MUC16 promotes EOC proliferation by regulating GLUT1 expression;Journal of Cellular and Molecular Medicine;2021-02-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3